The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Kymera Therapeutics Inc shares valued at $3,961,380 were sold by Jacobs Bruce N. on Sep 17 ’25. At $50.00 per share, Jacobs Bruce N. sold 79,220 shares. The insider’s holdings dropped to 227,409 shares worth approximately $12.97 million following the completion of this transaction.
Also, BRUCE N. JACOBS purchased 79,220 shares, netting a total of over 3,864,352 in proceeds.
Before that, Mainolfi Nello had sold 30,000 shares from its account. In a trade valued at $1,470,000, the Chief Executive Officer traded Kymera Therapeutics Inc shares for $49.00 each. Upon closing the transaction, the insider’s holdings decreased to 30,000 shares, worth approximately $37.66 million.
As published in a research note from H.C. Wainwright on September 18, 2025, Kymera Therapeutics Inc [KYMR] has been retained to a Buy and the price target has been revised to $70. Analysts at Barclays started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid September. As of September 16, 2025, RBC Capital Mkts has initiated its “an Outperform” rating for KYMR.
Analyzing KYMR Stock Performance
On last trading session, Kymera Therapeutics Inc [NASDAQ: KYMR] rose 1.30% to $57.02. The stock’s lowest price that day was $56.36, but it reached a high of $57.3875 in the same session. During the last five days, there has been a surge of approximately 1.82%. Over the course of the year, Kymera Therapeutics Inc shares have jumped approximately 35.09%. Shares of the company reached a 52-week high of $59.00 on 10/03/25 and a 52-week low of $19.44 on 04/09/25.
Support And Resistance Levels for Kymera Therapeutics Inc (KYMR)
According to the 24-hour chart, there is a support level at 56.46, which, if violated, would cause prices to drop to 55.90. In the upper region, resistance lies at 57.49. The next price resistance is at 57.95. RSI (Relative Strength Index) is 65.34 on the 14-day chart, showing neutral technical sentiment.
Is Kymera Therapeutics Inc subject to short interest?
Stocks of Kymera Therapeutics Inc saw a sharp steep in short interest on 2025-09-15 dropping by -0.16 million shares to 7.46 million. Data from Yahoo Finance shows that the short interest on 2025-08-15 was 7.61 million shares. A decline of -2.08% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 11.82 of the overall float, the days-to-cover ratio (short ratio) decline to 11.82.
Which companies own the most shares of Kymera Therapeutics Inc (KYMR)?
In terms of Kymera Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 63.5 in the next 12 months, up nearly 12.81% from the previous closing price of $56.29. Analysts anticipate Kymera Therapeutics Inc stock to reach 70 by 2025, with the lowest price target being 59. In spite of this, 8 analysts ranked Kymera Therapeutics Inc stock as Buy at the end of 2025. On July 03, 2025, Morgan Stanley assigned a price target of “an Overweight” to the stock and resumed coverage with a $70.
